KA-1874
/ KYinno
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 14, 2023
Bispecific antibody against TIGIT and PVRIG enhances antitumor immunity
(AACR 2023)
- "In cell-based luciferase reporter assays, KA-1874 blocks PVRIG and TIGIT-mediated inhibitory signaling and enhances CD3 signaling with EC50 of 1.1nM and 1.4nM respectively, while COM701 against PVRIG and EOS488 against TIGIT both with EC50 above 2nM. In comparison, KA-1874 or pembrolizumab alone fails to inhibit tumor growth. The above results indicate KA-1874 is an excellent candidate therapeutical antibody for cancer immunotherapy."
Oncology • NECTIN2 • PD-1 • PVR • TIGIT
1 to 1
Of
1
Go to page
1